01/05/2006 Press Release

BioAlliance Pharma Names François Sarkozy as Vice-Chairman of its Supervisory Board

Healthcare industry professional brings further operational and international experience to specialty pharma company

PARIS – January 5, 2006 – BioAlliance Pharma (Euronext Paris: BIO), an emerging specialty pharmaceutical company focused on the development of innovative therapeutics targeting drug resistance in cancer, HIV, and severe and opportunistic infections, announced today that François Sarkozy, MD, DEA, MBA, has been elected to serve as Vice-Chairman and independent member of its Supervisory Board (Conseil de Surveillance). Dr. Sarkozy is currently a Managing Partner of AEC Partners, a Paris-based healthcare consultancy.

“François is a quality addition to our board and we welcome the strong operational and international experience in healthcare he brings to the company ,” said Jean-Claude Deschamps, Chairman of the Supervisory Board.

“We look forward to benefiting from François’ extensive industry knowledge gained through his experience in a large global healthcare company and as a former practising physician in the Paris Public Hospital Authority,” said Dominique Costantini, MD, Chairman of the BioAlliance Management Board and CEO. “He will also bring a fresh perspective as BioAlliance makes the transition to a company focused on product commercialisation.”

Dr. Sarkozy, age 46, has served as a Managing Partner at AEC Partners since 2001, where his assignments have included international medical and marketing strategy, project and resource management, business development and negotiation analysis, commercialisation of new products and change management in mergers and reorganizations. Previously, during the period 1990-2000, he was Medical Director, France, for Aventis Pharma; Medical & Pharmaceutical Director, France, for Hoechst Marion Roussel, where he was also Vice President and Head of Global Portfolio & Project Management, the latter position including three years in the U.S.; earlier, he held various positions with Roussel-Uclaf, including International Development Director, International Clinical Development Head, and International Product Manager for Antibiotics. From 1983 to 1990, he was an Assistant in the Respiratory Physiology Department of the Paris Public Hospital Authority, where he also did his internship (Interne des Hôpitaux de Paris) in pediatrics. He holds an MBA from INSEAD.

About BioAlliance Pharma

BioAlliance Pharma is a privately held late stage biopharmaceutical company focused on drug resistance through development and commercialization of innovative therapeutics targeting markets in cancer, HIV, severe infections and supportive care. The company has two broad proprietary drug delivery platforms represented by the Lauriad® adhesive technology and the Transdrug® nanoparticle technology that provide multiple product opportunities. Together with a New Chemical Entities program focused on development of new drugs in oncology and HIV, the company is able to address worldwide markets in the EU, US, and Asia.

The company’s lead product within its adhesive technology program, the miconazole Lauriad® 50 mg Bioadhesive Buccal Tablet, is being investigated in two recently completed Phase III trials in Europe for treatment of oropharyngeal candidiasis in cancer and HIV patients. A pivotal Phase III trial in the same indication is planned for the U.S. later this year. A Phase I/II trial in hepatocellular carcinoma utilizing the company’s doxorubicin Transdrug® nanoparticle delivery technology is ongoing in Europe, where it has been granted an orphan medicinal product designation by the EMEA.

For additional company background, click here.

Company Contact

Richard Keatinge
Vice President, Business Development
BioAlliance Pharma SA
Tel : +33 (0) 1 45 58 76 00
richard.keatinge@bioalliancepharma.com

Media Contact
Andrew Lloyd & Associates
Andrew Lloyd
Tel : +44 1 273 675100
Gilles Petitot
Tel : +33 1 56 54 07 00